<DOC>
	<DOCNO>NCT01873001</DOCNO>
	<brief_summary>The purpose study evaluate effect abiraterone pharmacokinetics ( study body drug ) pioglitazone coadministered abiraterone acetate healthy adult male participant .</brief_summary>
	<brief_title>A Study Assess Effect Abiraterone ( JNJ-589485 ) Pharmacokinetics Pioglitazone Following Administration Abiraterone Acetate ( JNJ-212082 ) Pioglitazone HCl Tablets Healthy Male Participants</brief_title>
	<detailed_description>This open-label ( identity assign study drug know ) single-dose drug-drug interaction study assess effect abiraterone pioglitazone . Approximately 16 healthy adult male participant enrol study . The study consist screen phase , open-label treatment phase consist 2 single-dose treatment period , end-of-study withdrawal assessment do upon completion 72-hour pharmacokinetic sample Day 11 Period 2 upon withdrawal , follow-up visit 5 7 day last study procedure . The total study length 32 day . Participants receive pioglitazone alone Day 1 ( Period 1 ) study . On Day 8 ( Period 2 ) , participant receive single dose abiraterone acetate follow single dose pioglitazone one hour later . Successive pioglitazone administration separate washout period 7 day . Participants confine study center Day -1 Day 4 Period 1 Day 7 Day 11 Period 2 , least 10 hour study drug administration completion 72-hour blood sample collection period . A pharmacogenomic blood sample collect participant Day -1 . Safety monitor throughout study .</detailed_description>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Agrees protocoldefined use effective contraception 1 week receive last dose study drug Agrees donate sperm study 1 week receive last dose study drug Body mass index 18 30 kg/m2 body weight less 50 kg Blood pressure 90 140 mmHg systolic , high 90 mmHg diastolic A 12lead electrocardiogram consistent normal cardiac conduction function Nonsmoker Laboratory value within protocol define parameter History current clinically significant medical illness Clinically significant abnormal value hematology , clinical chemistry , urinalysis screen admission study center deem appropriate investigator Presence sexual dysfunction medical condition would affect sexual function Clinically significant abnormal physical examination , vital sign , 12lead electrocardiogram Use prescription nonprescription medication ( include vitamin herbal supplement ) first dose study drug schedule study completion History drug alcohol abuse within 3 year screen positive test result ( ) alcohol and/or drug abuse screen Day 1 Day 7 treatment period Known allergy study drug excipients formulation History stomach intestinal surgery resection would potentially alter absorption excretion orally administer drug ( appendectomy hernia repair allow ) Donated blood blood product substantial loss blood within 3 month first administration study drug intention donate blood blood product study Received experimental drug use experimental medical device within 1 month within period le 10 time drug 's halflife , whichever longer , first dose study drug schedule Positive test human immunodeficiency virus 1 2 antibody , hepatitis B surface antigen , hepatitis B core antibody hepatitis C antibody Preplanned surgery procedure would interfere conduct study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Drug-drug Interaction</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Abiraterone</keyword>
	<keyword>JNJ-589485</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>JNJ-212082</keyword>
	<keyword>Pioglitazone HCl</keyword>
</DOC>